Printer Friendly

BIOMERICA'S MONOCLONAL ANTIBODY TEST USED IN DOWN SYNDROME SCREENING STUDY

 BIOMERICA'S MONOCLONAL ANTIBODY TEST USED
 IN DOWN SYNDROME SCREENING STUDY
 NEWPORT BEACH, Calif., May 20 /PRNewswire/ -- Biomerica Inc. (NASDAQ: BMRA) has announced that its monoclonal antibody Free Alpha Subunit kit was used to study second-trimester chromosomally abnormal pregnancies. The study was coordinated at the University of New Mexico with the main focus being on trisomy 21 (Down's Syndrome) and trisomy 18 screening.
 The results (published in "Prenatal Diagnosis," vol. 12, 1992) reported that by using free alpha subunit, free beta subunit and their ratio, a specificity of 96 percent and sensitivity of 61 percent were achieved in detecting trisomy 21 (Down's Syndrome) pregnancies. In trisomy 18, the specificity and sensitivity were 96 percent and 86 percent, respectively. The study involved using amniotic fluid from 135 pregnancies in an effort to prenatally diagnose chromosomally anomalous problems. To date, trisomy 21 and trisomy 18 screening have been very difficult due to a lack of the availability of a sensitive and specific test method. Although this study provides a very useful outlook for the Biomerica Alpha Subunit Kit in Down's Syndrome screening, the clinical applicability of this knowledge in prenatal testing remains to be determined.
 Down's Syndrome (trisomy 21) is the most chromosomal disorder. Both trisomy 21 and trisomy 18 are usually accompanied by moderate to severe mental retardation. The risk of having a baby with Down's Syndrome is greater in women who are 35 years of age or older at the time of delivery.
 Biomerica is a medical company engaged in the development, manufacture and marketing of medical diagnostic products including home self-testing.
 -0- 5/20/92
 /CONTACT: Joseph H. Irani, president of Biomerica, 714-645-2111/
 (BMRA) CO: Biomerica Inc. ST: California IN: MTC SU:


SD-AL -- LA025 -- 2351 05/20/92 13:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1992
Words:291
Previous Article:GEICO ANNOUNCES RECORD DATE FOR STOCK SPLIT, SHARE REPURCHASE AND DECLARES DIVIDEND
Next Article:NEW FITCH STUDY RANKS BOND INSURERS FOR FIRST TIME -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
BIOMERICA SIGNS AN AGREEMENT WITH SAV-ON/OSCO FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA SIGNS HOOK DRUGS FOR DISTRIBUTION OF STOOL BLOOD TEST KIT
BIOMERICA'S EZ DETECT(TM) TO BE USED IN COLON CANCER SCREENING
BIOMERICA'S ULCER TEST APPROVED IN JAPAN
BIOMERICA RECEIVES FDA CLEARANCE FORTHYROID AUTOIMMUNE DISEASE DETECTION TEST
BIOMERICA SIGNS AGREEMENT TO PROVIDE PRODUCT TO BIORAD
BIOMERICA RECEIVES FDA CLEARANCE FOR AUTOIMMUNE DISEASE DETECTION TEST
NEW AIDS TEST
Biomerica and Bentley Pharmaceuticals Reach Marketing and Distribution Agreement
Biomerica's EZ Detect(TM) Test to Benefit From Latest Study Recommending At-Home Colorectal Screening Tests.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters